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Objective: Children and adolescents with bipolar disorder are also at high risk of having 
comorbid attention-deﬁ  cit hyperactivity disorder (ADHD). The objective of this study was to 
estimate improvement in ADHD symptoms in children with bipolar disorder.
Methods: This was an open-label, study of risperidone monotherapy for the treatment of pedi-
atric bipolar disorder. Thirty-one children and adolescents 4–15 years of age (7.2 ± 2.8 years) 
of both sexes (71%, N = 22 male) with pediatric bipolar disorder (YMRS score = 32.9 ± 8.8) 
and ADHD (ADHD-RS score = 37.9 ± 8.9) were included in these analyses.
Results: Improvement in ADHD symptoms was contingent on improvement in manic symp-
toms. Although both hyperactive/impulsive (−7.5 ± 5.5.6, p   0.05) and inattentive (−6.8 ± 5.0, 
p   0.05) ADHD symptoms were signiﬁ  cantly improved with risperidone, improvement was 
modest, and only 29% of subjects (N = 6) showed a 30% reduction in ADHD rating scale scores 
and had a CGI-I   2.
Conclusions: These results suggest that that treatment with risperidone is associated with 
tangible but generally modest improvement of symptoms of ADHD in children with bipolar 
disorder.
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Introduction
Childhood bipolar disorder (BPD) is among the most severely disabling psychiatric 
conditions affecting children (Faedda et al 1995; Geller and Luby 1997; Biederman 
et al 2000). It is associated with great severity of the illness including psychosis, mixed 
mania, and high rates of aggression and impairment (Strober et al 1995; Wozniak et al 
1995; Geller et al 2002).
In a recent prospective, open-label, treatment trial (Biederman et al 2005b), we 
documented that treatment with risperidone was associated with clinically and statisti-
cally signiﬁ  cant improvement in manic symptomatology indexed through the Young 
Mania Rating Scale (YMRS ) (−14.4 ± 10.6, p   0.0001). Using predeﬁ  ned criteria 
for improvement, the response rate for manic symptoms was 70% (Biederman et al 
2005b). However, since studies of children with bipolar disorder consistently docu-
ment a very high degree of overlap between pediatric bipolar disorder and attention-
deﬁ  cit hyperactivity disorder (ADHD) (Borchardt and Bernstein 1995; Geller et al 
1995; West et al 1995; Wozniak et al 1995; Biederman et al 2000; Biederman et al 
2004), whether treatment with risperidone is also effective in the treatment of ADHD 
symptomatology in children with bipolar disorder remains uncertain.
The available literature suggests a role for risperidone in the management of 
ADHD symptoms in the context of disruptive behavior disorders. In a randomized 
placebo-controlled clinical trial of children with disruptive behavior disorders and 
subaverage intelligence, Aman and colleagues (2004) showed that risperidone was 
associated with improvement in symptoms of hyperactivity, regardless of concomitant Neuropsychiatric Disease and Treatment 2008:4(1) 204
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stimulant use. Likewise, in a single blind randomized trial 
of methylphenidate or risperidone treatment of ADHD chil-
dren with moderate mental retardation (Correia Filho et al 
2005), risperidone was effective as methylphenidate for 
ADHD symptoms. Eapen and colleagues (2005) examined a 
small sample of children with disruptive behavior disorders, 
ADHD and aggression and demonstrated a positive clinical 
response in 9 of 12 children treated. Yet, to the best of our 
knowledge no study has speciﬁ  cally addressed the impact of 
risperidone in the treatment of comorbid ADHD in children 
with bipolar disorder.
Whether treatment with risperidone is effective in the 
treatment of ADHD symptoms in children with bipolar dis-
order is of high clinical signiﬁ  cance. Considering the high 
overlap between bipolar disorder and ADHD and the high 
morbidity associated with ADHD, addressing this disorder 
can greatly facilitate the management of children with bipolar 
disorder. Since traditional treatments for ADHD can exac-
erbate mania, the identiﬁ  cation of alternative treatments to 
manage ADHD symptomatology in children with bipolar 
disorder devoid of a destabilizing potential are needed.
The objective of this study was to evaluate the effects of 
risperidone monotherapy on ADHD symptoms in a sample 
of children with bipolar disorder. To this end we conducted 
secondary analyses examining response to ADHD symp-
toms in a prospective open-label trial of risperidone utiliz-
ing systematic clinical assessments of ADHD severity and 
improvement. Based on the literature, we hypothesized that 
ADHD symptoms would improve in children with bipolar 
disorder and comorbid ADHD and that improvement in 
ADHD symptoms in bipolar children will only be observable 
in those who improved their symptoms of mania.
Methods
As previously reported (Biederman et al 2005a, 2005b), the 
study consisted of an 8-week, open-label treatment trial of 
risperidone monotherapy in children with bipolar disorder. 
All study procedures were reviewed and approved by our 
Institutional Review Board for Research on Human Subjects. 
All subjects’ parents or guardians signed written informed 
consent forms and children ( 7 years of age) signed written 
assent forms.
Male or female subjects 4–17 years of age were included 
in the trial. Each subject met criteria for DSM-IV bipolar I 
disorder, or bipolar disorder not otherwise speciﬁ  ed (NOS) 
and were currently displaying manic or mixed symptoms 
(with or without psychotic features) based on clinical assess-
ment by a board-certiﬁ  ed child and adolescent psychiatrist. 
The DSM-IV requires subjects met criterion A for a period 
of extreme and persistently elevated, expansive or irritable 
mood lasting at least one week, plus criterion B, manifested 
by three (four if the mood is irritable only) of seven symptoms 
during the period of mood disturbance. Also recorded was the 
onset of the ﬁ  rst episode, the number of episodes and the total 
duration of illness. BPD II disorder was deﬁ  ned according to 
the DSM-IV as hypomania (an abnormal mood lasting at least 
4 days), and BPD NOS was deﬁ  ned as a severe manic mood 
disturbance that did not meet either time criteria (at least 4 
days) or had fewer elements in criterion B (only required 2 
items for elation and 3 for irritability).
In order to assess the lifetime and current rates of psy-
chiatric comorbidity structured diagnostic interview Kiddie 
Schedule of Affective Disorders and Schizophrenia Epide-
miological Version (KSADS) (Ambrosini 2000) were con-
ducted with mothers and children over the age of 12 years. 
KSADS interviews were administered by highly trained and 
supervised non-clinician interviewers. All diagnoses were 
reviewed by a sign-off committee of experienced board 
certiﬁ  ed child and adolescent psychiatrists chaired by the 
senior investigator (JB).
In addition, all children were clinically assessed for 
bipolar disorder and other psychiatric comorbidity by board-
certiﬁ  ed or board-eligible child and adolescent psychiatrists. 
During this baseline evaluation the clinicians completed 
the Young Mania Rating Scale (YMRS) (Young et al 1978; 
Youngstrom et al 2002) as a measure of current symptom 
severity of mania. To be included in the study, subjects must 
have had a score of 15 or greater on the YMRS. ADHD sever-
ity was assessed at baseline, week 4 and endpoint with the 
clinician rated ADHD Rating Scale (ADHD-RS). To assess 
clinically signiﬁ  cant severity and improvement relative to 
baseline, we used the NIMH Clinical Global Impression 
(CGI) severity (CGI-S), and improvement (CGI-I) scales 
(National Institute of Mental Health 1985) rated separately 
for symptoms of mania, depression, and ADHD. The score 
for the CGI-S ranges from 1 (normal, not at all ill) to 7 
(among the most extremely ill patients). The score for the 
CGI-I ranges from 1 (very much improved) to 7 (very much 
worse). Subjects were considered ADHD responders a priori 
if they had at least a 30% reduction on the ADHD-RS and an 
ADHD CGI-I   2 (much or very much improved).
We excluded subjects with any serious, unstable 
illness including hepatic, renal, gastroenterologic, respira-
tory, cardiovascular (including ischemic heart disease), 
endocrinologic, neurologic, immunologic, or hematologic 
disease. Subjects with DSM-IV substance (except nicotine Neuropsychiatric Disease and Treatment 2008:4(1) 205
Risperidone for ADHD with bipolar disorder
or caffeine) dependence within past 6 months or who were 
judged to be at serious suicidal risk were also excluded from 
participation. No subjects were tapered off of their current 
antimanic medications for the purpose of enrolling in this 
study unless the current treatment was determined to be inef-
fective as indicated by continuing to meet entrance criteria 
(active symptoms of mania and a YMRS Score of  15). 
Mood stabilizers, anticonvulsants, and other neuroleptic 
therapy, were not allowed during this study. Antidepressants 
were exclusionary to the study.
Risperidone was initiated at an open-label dose of 0.25 
mg/day for children  12 years and 0.5 mg/day for older 
youth to be increased weekly according to response and 
tolerability to a maximum does of 2.0 mg/day for  12 and 
up to 4.0 mg/day for older youth. Given the strong overlap of 
juvenile bipolar disorder with attention deﬁ  cit hyperactivity 
disorder, the psychostimulants methylphenidate hydrochlo-
ride, dextroamphetamine sulfate and mixed amphetamine 
salts were allowed during the study if, in the clinician’s judg-
ment, it was in the best interest of the subjects to continue 
this treatment or if the subject did not wish to stop stimulant 
treatment and only if the subject had been on a stable dose for 
at least 30 days. If extrapyramidal symptoms occured, benz-
tropine mesylate was allowed in doses of up to a maximum 
of 2 mg/day. The use of the benzodiazepine lorazepam was 
permitted during the study in doses of 2 mg or less per day. 
Nonpharmacological treatments such as individual, family, or 
group therapy were allowed if they were in place before the 
subject joined the study and if the therapy regimen remained 
the same throughout the study.
Safety was assessed at each visit using spontaneous 
reports of treatment-emergent adverse events, changes in 
vital signs and laboratory measures. Blood pressure and 
weight were recorded at each visit. Prolactin, glucose, and 
lipid levels were obtained at baseline and post treatment.
Statistical analysis
Generalized estimating equation models were used to ana-
lyze the repeated measures of the study as implemented in 
STATA. All analyses were intention to treat (ITT) with the 
last observation (LOC) carried forward for subjects that did 
not complete the entire study. Statistical signiﬁ  cance was 
determined at p   0.05.
Results
Although 59 children and adolescents were enrolled in this 
open-label treatment trial of risperidone monotherapy, only 
36 had available ratings on the ADHD-RS. Five subjects 
who were receiving stimulant medications were excluded 
from further analyses. Thus, the ﬁ  nal sample consisted of 31 
children and adolescents 4–15 years of age (7.2 ± 2.8 years) 
of both sexes (71%, N = 22 male) with pediatric bipolar 
disorder (YMRS score = 32.9 ± 8.8) and ADHD (ADHD-RS 
score  = 37.9 ± 8.9). The mean dose of risperidone at endpoint 
was 1.47 ± 0.67 mg/day and 68% (N = 21) were considered 
much or very much improved ( 2) on the mania-speciﬁ  c 
CGI-I rating.
As shown in Table 1, ADHD symptom scores at baseline 
were slightly higher in the group that did not have an adequate 
antimanic response to risperidone. A statistically signiﬁ  cant 
Table 1 ADHD rating scale scores at baseline and endpoint in 31 bipolar youth
 Mania  CGI-I    2 Mania  CGI-I    2
 N  = 21  N = 10 
 Mean  ± SD  Mean ± SD  Statistic
ADHD RS total     
Baseline 35.4  ± 8.5  43.3 ± 7.3  F(1,29)–6.3, p = 0.02
Endpoint 21.2  ± 10.6* 39.0  ± 7.8  F(1,29)–22.2, p = 0.001
Change  −14.2 ± 10.3  −4.3 ± 9.1  F(1,29)–6.8, p = 0.02
ADHD RS IA     
Baseline 17.8  ± 4.4  19.4 ± 6.3  F(1,29)–0.6, p = 0.9
Endpoint 11.1  ± 5.1* 17.4  ± 5.8  F(1,29)–9.4, p = 0.005
Change  −6.8 ± 5.0  −2.0 ± 6.7  F(1,29) = 5.3, p = 0.03
ADHD RS HI     
Baseline 17.6  ± 5.8  23.9 ± 2.6  F(1,29)–10.6, p = 0.003
Endpoint 10.1  ± 6.7* 21.6  ± 4.7  F(1,29)–23.3, p   0.001
Change  −7.5 ± 5.6  −2.3 ± 4.5  F(1,29) = 6.4, p = 0.02
Notes: *p   0.05 within responder group from baseline to endpoint.
Abbreviations: ADHD-RS, attention deﬁ  cit hyperactivity disorder rating scale;   ADHD RS IA, attention deﬁ  cit hyperactivity disorder rating scale inattentive;   ADHD RS HI, 
attention deﬁ  cit hyperactivity disorder rating scale hyperactivity index.Neuropsychiatric Disease and Treatment 2008:4(1) 206
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change from baseline to endpoint in ADHD symptoms was 
observed only in subjects whose mania responded to ris-
peridone. In these subjects, both inattentive and hyperactive 
impulsive symptoms signiﬁ  cantly improved. Although 62% 
of mania responders showed a 30% reduction in ADHD-RS 
scores, only 35% were rated as much or very much improved 
on the ADHD speciﬁ  c CGI-I ratings and 29% were rated as 
responders (CGI   2 plus ADHD-RS improvement of 30% 
or more).
The most commonly spontaneously reported adverse 
effects were common cold (39%), increased appetite (29%), 
headache (20%), and sedation (22%). There were no signiﬁ  -
cant differences between baseline and endpoint in metabolic 
or cardiac parameters with the exception of a three-fold 
increase in prolactin levels (from 13.4 ± 10.1 ng/dL to 
41.3 ± 23.2 ng/dL, F(1,30) = 28.7, p   0.001). In addition 
there was a statistically signiﬁ  cant weight gain over the course 
of the trial (2.2 ± 2.2 kg; F(1,30) = 19.6, p   0.001).
Discussion
In this prospective, open-label, 8-week treatment trial of 
risperidone monotherapy in youth with bipolar disorder, 
we found that treatment with risperidone was associated 
with statistically signiﬁ  cant improvement in symptoms of 
ADHD that included both symptoms of inattention and 
hyperactivity. Although improvement in ADHD symptoms 
was generally modest, these results suggest that risperidone 
may partially treat symptoms of ADHD in children with 
bipolar disorder.
These results are consistent with two previous controlled 
studies of risperidone that documented improvement in 
ADHD symptoms in children with disruptive behavior 
disorders and sub average intelligence (Aman et al 2004; 
Correia Filho et al 2005). The observation that improvement 
in ADHD symptomatology included both symptoms of 
inattention and hyperactivity suggests that this improve-
ment was not due simply to the non-speciﬁ  c effects of 
risperidone on agitation and hyperactivity associated with 
bipolar disorder.
Our ﬁ  ndings documenting that improvement in ADHD 
symptoms in bipolar children associated with risperidone 
was limited to those who had an adequate antimanic response 
are consistent with results from our previous chart review 
(Biederman et al 1999). That study also documented that the 
presence of mania interfered with the improvement of ADHD 
symptomatology during anti-ADHD pharmacotherapy and 
that ADHD symptoms were much more likely to improve 
after mood stabilization.
It is noteworthy that despite the observation that 62% of 
subjects showed a 30% reduction in ADHD symptoms, the 
scores on the ADHD rating scales at endpoint continued to 
be moderately elevated (21.2 ± 10.6) indicative of residual 
ADHD symptomatology. Although more work is needed to 
evaluate the clinical impact of this level of residual ADHD 
and whether they warrant additional treatments for ADHD in 
this population, the partial response to risperidone in ADHD 
symptomatology needs to be weighed against concerns about 
the potential destabilizing effects of traditional anti ADHD 
medications.
Our results need to be viewed in light of methodological 
limitations. Since this was an open study, the assessments 
were not blind to treatment. Although ﬁ  rmer conclusions 
regarding the role of risperidone in the treatment of ADHD 
symptoms in the context of pediatric bipolar disorder await 
results from randomized, double-blind, controlled clinical 
trials, open studies such as this represent an essential ﬁ  rst 
step in developing hypotheses on therapeutic approaches 
to children with bipolar disorder. Despite these limitations, 
Table 2 ADHD rate of response in 31 bipolar youth at endpoint
 Mania  CGI-I    2  Mania CGI-I   2
 N  = 21  N = 10 
  N (%)  N (%)  Statistic
ADHD RS total     
30% Improvement  13 (62)  2 (20)  χ2(1) = 4.8, p = 0.03
50% Improvement  6 (29)  0 (0)  χ2(1) = 3.5, p = 0.06
ADHD CGI-I     
Much Improved  5 (24)  0 (0)  χ2(1) = 3.1, p = 0.08*
Very Much Improved  2 (10)  0 (0) 
ADHD Responder  6 (29%)  0 (0%)  χ2(1) = 3.5, p = 0.06
Notes: *Comparison made between CGI-I   2 versus CGI-I   2.
Abbreviations: ADHD-RS, attention deﬁ  cit hyperactivity disorder rating scale; ADHD-CGI-I, attention deﬁ  cit hyperactivity disorder-Clinical Global Impressions Improve-
ment Scale.Neuropsychiatric Disease and Treatment 2008:4(1) 207
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our results suggest that risperidone monotherapy may have 
modest beneﬁ  cial effects in controlling ADHD symptoms in 
youth with bipolar disorder.
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